Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about making homemade topical finasteride. Propylene glycol is suggested to help the solution stay on the scalp longer.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

The conversation discusses the availability and legitimacy of a hair loss treatment called PP405-3HP. Users express skepticism about its release and reference patent information.

A user is interested in creating a hair growth serum using oleic acid, palmitoleic acid, and anhydrous ethanol, and seeks advice on sourcing these ingredients. Another user plans to mix these with minoxidil, which already contains ethanol, and mentions using RU58841.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

The conversation discusses using stemoxydine as a carrier for RU58841 and the search for affordable, premixed PG+E. Minoxidil is considered as an alternative, but simplicity is preferred.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Pumpkin seed oil dosage for hair loss, with a focus on transitioning from capsules to liquid form. The discussion includes dosage recommendations and absorption differences between capsule and liquid forms.

Rosemary oil can smell like camphor and is considered okay for hair use. The user bought a large bottle from a wholesaler to save costs.

The user is seeking advice for frizzy hair, having tried coconut oil without success and considering Olaplex products. They are looking for effective product recommendations.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Applying oils like coconut, jojoba, and castor to hair, with methods including mixing oils and using them overnight or in a spray bottle for scalp and hair health. Users share their specific oil ratios and application techniques to avoid excessive thickness and maintain hair health.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.